Biodexa Pharmaceuticals PLC Files Form 6-K

Ticker: BDRX · Form: 6-K · Filed: May 21, 2024 · CIK: 1643918

Biodexa Pharmaceuticals PLC 6-K Filing Summary
FieldDetail
CompanyBiodexa Pharmaceuticals PLC (BDRX)
Form Type6-K
Filed DateMay 21, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: filing, registration-statement, disclosure

Related Tickers: BDRX

TL;DR

Biodexa (BDRX) filed a 6-K, incorporating an exhibit into its F-3 and F-1 filings. No new material info, just housekeeping.

AI Summary

Biodexa Pharmaceuticals PLC filed a Form 6-K on May 21, 2024, to incorporate by reference Exhibit 99.1 into its existing Registration Statements on Form F-3 (File No. 333-233901) and Form F-1 (File No. 333-240984). The company, formerly known as Midatech Pharma Plc, is based in Cardiff, United Kingdom.

Why It Matters

This filing indicates that Biodexa Pharmaceuticals PLC is updating or referencing material information within its existing SEC registration statements, which could be relevant for investors tracking the company's disclosures.

Risk Assessment

Risk Level: low — This filing is primarily procedural, incorporating an exhibit into existing registration statements, and does not appear to contain new material financial or operational information.

Key Players & Entities

FAQ

What is the purpose of this Form 6-K filing?

The purpose of this Form 6-K is to incorporate by reference Exhibit 99.1 into the Company's Registration Statements on Form F-3 (File No. 333-233901) and Form F-1 (File No. 333-240984).

When was this Form 6-K filed?

This Form 6-K was filed on May 21, 2024.

What is the company's former name?

The company's former name was Midatech Pharma Plc.

Where is Biodexa Pharmaceuticals PLC located?

Biodexa Pharmaceuticals PLC is located at 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom.

Does the company file annual reports under Form 20-F or 40-F?

The registrant indicates it files annual reports under cover of Form 20-F.

Filing Stats: 204 words · 1 min read · ~1 pages · Grade level 11.5 · Accepted 2024-05-21 10:53:19

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Biodexa Pharmaceuticals PLC (Registrant) Date: May 21, 2024 /s/ Stephen Stamp Stephen Stamp Chief Executive Officer, Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing